MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control

 With No Titration, Demonstrated Compelling Maximum Weight Loss of 6.3% and 
Mean Weight Loss of 4.3% at Day 26 at 32 mg Dose (p=0.0005)

Demonstrated Strong Signal of GLP-1R Efficacy with Maximum Lowering of Fasted Glucose of -18 mg/dL 
and Mean Lowering of -5.3 mg/dL at Day 26 at 32 mg Dose

Read more at prnewswire.com